Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: A randomized trial

Kurt Kroenke, Suzanne L. West, Ralph Swindle, Alicia Gilsenan, George J. Eckert, Rowena Dolor, Paul Stang, Xiao Hua Zhou, Ron Hays, Morris Weinberger

Research output: Contribution to journalArticle

242 Citations (Scopus)

Abstract

Context: Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed class of antidepressant, yet it is not known whether one SSRI is more effective than another. Objective: To compare the effectiveness of 3 SSRIs (paroxetine, fluoxetine, and sertraline) in depressed primary care patients. Design: Open-label, randomized, intention-to-treat trial, with patient enrollment occurring in April-November 1999. Setting: Thirty-seven clinics in 2 US primary care research networks. Patients: A total of 573 depressed adult patients for whom their primary care physician thought that antidepressant therapy was warranted and who completed a baseline interview. Interventions: Patients were randomly assigned to receive paroxetine (n = 189), fluoxetine (n = 193), or sertraline (n = 191) for 9 months. Primary care physicians were allowed to switch patients to a different SSRI or non-SSRI antidepressant if they did not adequately respond to or tolerate the initial SSRI. Main Outcome Measures: The primary outcome measure was change in the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) Mental Component Summary score (range, 0-100), compared across treatment groups at 1, 3, 6, and 9 months. Secondary outcomes included other depression and psychological measures, multiple measures of social and work functioning, and other domains of healthrelated quality of life, such as physical functioning, concentration and memory, vitality, bodily pain, sleep, and sexual functioning. Results: Follow-up interviews were successfully completed in 94% of patients at 1 month, 87% at 3 months, 84% at 6 months, and 79% at 9 months. Responses to the 3 SSRIs were comparable on all measures and at all time points. The mean change in the SF-36 Mental Component Summary score at 9 months was + 15.8 in the paroxetine group, + 15.1 in the fluoxetine group, and + 17.4 in the sertraline group. The drugs were also associated with similar incidences of adverse effects and discontinuation rates. Conclusions: The SSRI antidepressants paroxetine, fluoxetine, and sertraline were similar in effectiveness for depressive symptoms as well as multiple domains of health-related quality of life over the entire 9 months of this trial.

Original languageEnglish
Pages (from-to)2947-2955
Number of pages9
JournalJournal of the American Medical Association
Volume286
Issue number23
StatePublished - Dec 19 2001

Fingerprint

Sertraline
Paroxetine
Fluoxetine
Serotonin Uptake Inhibitors
Primary Health Care
Antidepressive Agents
Outcome Assessment (Health Care)
Primary Care Physicians
Quality of Life
Interviews
Depression
Health Surveys
Social Work
Sleep
Psychology
Pain
Incidence
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kroenke, K., West, S. L., Swindle, R., Gilsenan, A., Eckert, G. J., Dolor, R., ... Weinberger, M. (2001). Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: A randomized trial. Journal of the American Medical Association, 286(23), 2947-2955.

Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care : A randomized trial. / Kroenke, Kurt; West, Suzanne L.; Swindle, Ralph; Gilsenan, Alicia; Eckert, George J.; Dolor, Rowena; Stang, Paul; Zhou, Xiao Hua; Hays, Ron; Weinberger, Morris.

In: Journal of the American Medical Association, Vol. 286, No. 23, 19.12.2001, p. 2947-2955.

Research output: Contribution to journalArticle

Kroenke, K, West, SL, Swindle, R, Gilsenan, A, Eckert, GJ, Dolor, R, Stang, P, Zhou, XH, Hays, R & Weinberger, M 2001, 'Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: A randomized trial', Journal of the American Medical Association, vol. 286, no. 23, pp. 2947-2955.
Kroenke, Kurt ; West, Suzanne L. ; Swindle, Ralph ; Gilsenan, Alicia ; Eckert, George J. ; Dolor, Rowena ; Stang, Paul ; Zhou, Xiao Hua ; Hays, Ron ; Weinberger, Morris. / Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care : A randomized trial. In: Journal of the American Medical Association. 2001 ; Vol. 286, No. 23. pp. 2947-2955.
@article{f618f715620049d3a61a8cb680c9447d,
title = "Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: A randomized trial",
abstract = "Context: Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed class of antidepressant, yet it is not known whether one SSRI is more effective than another. Objective: To compare the effectiveness of 3 SSRIs (paroxetine, fluoxetine, and sertraline) in depressed primary care patients. Design: Open-label, randomized, intention-to-treat trial, with patient enrollment occurring in April-November 1999. Setting: Thirty-seven clinics in 2 US primary care research networks. Patients: A total of 573 depressed adult patients for whom their primary care physician thought that antidepressant therapy was warranted and who completed a baseline interview. Interventions: Patients were randomly assigned to receive paroxetine (n = 189), fluoxetine (n = 193), or sertraline (n = 191) for 9 months. Primary care physicians were allowed to switch patients to a different SSRI or non-SSRI antidepressant if they did not adequately respond to or tolerate the initial SSRI. Main Outcome Measures: The primary outcome measure was change in the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) Mental Component Summary score (range, 0-100), compared across treatment groups at 1, 3, 6, and 9 months. Secondary outcomes included other depression and psychological measures, multiple measures of social and work functioning, and other domains of healthrelated quality of life, such as physical functioning, concentration and memory, vitality, bodily pain, sleep, and sexual functioning. Results: Follow-up interviews were successfully completed in 94{\%} of patients at 1 month, 87{\%} at 3 months, 84{\%} at 6 months, and 79{\%} at 9 months. Responses to the 3 SSRIs were comparable on all measures and at all time points. The mean change in the SF-36 Mental Component Summary score at 9 months was + 15.8 in the paroxetine group, + 15.1 in the fluoxetine group, and + 17.4 in the sertraline group. The drugs were also associated with similar incidences of adverse effects and discontinuation rates. Conclusions: The SSRI antidepressants paroxetine, fluoxetine, and sertraline were similar in effectiveness for depressive symptoms as well as multiple domains of health-related quality of life over the entire 9 months of this trial.",
author = "Kurt Kroenke and West, {Suzanne L.} and Ralph Swindle and Alicia Gilsenan and Eckert, {George J.} and Rowena Dolor and Paul Stang and Zhou, {Xiao Hua} and Ron Hays and Morris Weinberger",
year = "2001",
month = "12",
day = "19",
language = "English",
volume = "286",
pages = "2947--2955",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "23",

}

TY - JOUR

T1 - Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care

T2 - A randomized trial

AU - Kroenke, Kurt

AU - West, Suzanne L.

AU - Swindle, Ralph

AU - Gilsenan, Alicia

AU - Eckert, George J.

AU - Dolor, Rowena

AU - Stang, Paul

AU - Zhou, Xiao Hua

AU - Hays, Ron

AU - Weinberger, Morris

PY - 2001/12/19

Y1 - 2001/12/19

N2 - Context: Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed class of antidepressant, yet it is not known whether one SSRI is more effective than another. Objective: To compare the effectiveness of 3 SSRIs (paroxetine, fluoxetine, and sertraline) in depressed primary care patients. Design: Open-label, randomized, intention-to-treat trial, with patient enrollment occurring in April-November 1999. Setting: Thirty-seven clinics in 2 US primary care research networks. Patients: A total of 573 depressed adult patients for whom their primary care physician thought that antidepressant therapy was warranted and who completed a baseline interview. Interventions: Patients were randomly assigned to receive paroxetine (n = 189), fluoxetine (n = 193), or sertraline (n = 191) for 9 months. Primary care physicians were allowed to switch patients to a different SSRI or non-SSRI antidepressant if they did not adequately respond to or tolerate the initial SSRI. Main Outcome Measures: The primary outcome measure was change in the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) Mental Component Summary score (range, 0-100), compared across treatment groups at 1, 3, 6, and 9 months. Secondary outcomes included other depression and psychological measures, multiple measures of social and work functioning, and other domains of healthrelated quality of life, such as physical functioning, concentration and memory, vitality, bodily pain, sleep, and sexual functioning. Results: Follow-up interviews were successfully completed in 94% of patients at 1 month, 87% at 3 months, 84% at 6 months, and 79% at 9 months. Responses to the 3 SSRIs were comparable on all measures and at all time points. The mean change in the SF-36 Mental Component Summary score at 9 months was + 15.8 in the paroxetine group, + 15.1 in the fluoxetine group, and + 17.4 in the sertraline group. The drugs were also associated with similar incidences of adverse effects and discontinuation rates. Conclusions: The SSRI antidepressants paroxetine, fluoxetine, and sertraline were similar in effectiveness for depressive symptoms as well as multiple domains of health-related quality of life over the entire 9 months of this trial.

AB - Context: Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed class of antidepressant, yet it is not known whether one SSRI is more effective than another. Objective: To compare the effectiveness of 3 SSRIs (paroxetine, fluoxetine, and sertraline) in depressed primary care patients. Design: Open-label, randomized, intention-to-treat trial, with patient enrollment occurring in April-November 1999. Setting: Thirty-seven clinics in 2 US primary care research networks. Patients: A total of 573 depressed adult patients for whom their primary care physician thought that antidepressant therapy was warranted and who completed a baseline interview. Interventions: Patients were randomly assigned to receive paroxetine (n = 189), fluoxetine (n = 193), or sertraline (n = 191) for 9 months. Primary care physicians were allowed to switch patients to a different SSRI or non-SSRI antidepressant if they did not adequately respond to or tolerate the initial SSRI. Main Outcome Measures: The primary outcome measure was change in the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) Mental Component Summary score (range, 0-100), compared across treatment groups at 1, 3, 6, and 9 months. Secondary outcomes included other depression and psychological measures, multiple measures of social and work functioning, and other domains of healthrelated quality of life, such as physical functioning, concentration and memory, vitality, bodily pain, sleep, and sexual functioning. Results: Follow-up interviews were successfully completed in 94% of patients at 1 month, 87% at 3 months, 84% at 6 months, and 79% at 9 months. Responses to the 3 SSRIs were comparable on all measures and at all time points. The mean change in the SF-36 Mental Component Summary score at 9 months was + 15.8 in the paroxetine group, + 15.1 in the fluoxetine group, and + 17.4 in the sertraline group. The drugs were also associated with similar incidences of adverse effects and discontinuation rates. Conclusions: The SSRI antidepressants paroxetine, fluoxetine, and sertraline were similar in effectiveness for depressive symptoms as well as multiple domains of health-related quality of life over the entire 9 months of this trial.

UR - http://www.scopus.com/inward/record.url?scp=0035915312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035915312&partnerID=8YFLogxK

M3 - Article

C2 - 11743835

AN - SCOPUS:0035915312

VL - 286

SP - 2947

EP - 2955

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 23

ER -